Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro

被引：29

作者：

Xu, Ren-ai ^{[1
]}

Wen, Jian ^{[2
]}

Tang, Pengfei ^{[2
]}

Wang, Chenchen ^{[2
]}

Xie, Saili ^{[1
]}

Zhang, Bo-wen ^{[2
]}

Zhou, Quan ^{[2
]}

Cai, Jian-ping ^{[3
]}

Hu, Guo-xin ^{[2
]}

机构：

[1] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Peoples R China

[2] Wenzhou Med Univ, Sch Pharmaceut Sci, Dept Pharmacol, Wenzhou, Peoples R China

[3] Beijing Hosp, Natl Ctr Gerontol, Key Lab Geriatr, Minist Hlth,MOH, Beijing, Peoples R China

来源：

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY | 2018年 / 122卷 / 04期

关键词：

LIVER-MICROSOMES; TARGETING BTK; IDENTIFICATION; POLYMORPHISM; NIFEDIPINE; OXIDATION; JAPANESE; ENZYMES; MODELS; DRUGS;

D O I：

10.1111/bcpt.12934

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cytochrome P450 3A4 (CYP3A4) is quantitatively the most important P450 enzyme in adults. It is suggested that CYP3A4 genetic polymorphisms may influence the rate of the metabolism and elimination of CYP3A4 substrates in human beings. Ibrutinib is an anticancer drug and primarily metabolized by CYP3A4. The aim of this study was to systematically investigate the effects of 22 CYP3A4 protein variants on the metabolism of ibrutinib in vitro. When compared with wild-type CYP3A4.1, two variants (CYP3A4.17 and CYP3A4.24) had no detectable enzyme activity; five variants (CYP3A4.10, .11, .18, .23 and .33) exhibited no significant differences; another five variants (CYP3A4.3, .4, .9, .19 and .34) showed increased intrinsic clearance values, while the remaining nine variants (CYP3A4.2, .5, .14, .15, .16, .28, .29, .31 and .32) displayed decreased enzymatic activities in different degrees. As the first study of 22 CYP3A4 protein variants in ibrutinib metabolism, these comprehensive data may help in the clinical assessment of the metabolism and elimination of ibrutinib and also offer a reference to the personalized treatment of ibrutinib in clinic.

引用

页码：383 / 387

页数：5

共 28 条

[1] A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach [J].

Andreu, Franc ;

Colom, Helena ;

Elens, Laure ;

van Gelder, Teun ;

van Schaik, Ronald H. N. ;

Hesselink, Dennis A. ;

Bestard, Oriol ;

Torras, Joan ;

Cruzado, Josep M. ;

Grinyo, Josep M. ;

Lloberas, Nuria .

CLINICAL PHARMACOKINETICS, 2017, 56 (08) :963-975

[2] A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: Structure-kinetics relationship assessment [J].

Bu, HZ .

CURRENT DRUG METABOLISM, 2006, 7 (03) :231-249

[3] Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Flinn, Ian W. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Grant, Barbara ;

Sharman, Jeff P. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Sukbuntherng, Juthamas ;

Chang, Betty Y. ;

Clow, Fong ;

Hedrick, Eric ;

Buggy, Joseph J. ;

James, Danelle F. ;

O'Brien, Susan .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) :32-42

[4]

Dai D, 2001, J PHARMACOL EXP THER, V299, P825

[5] Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants [J].

de Jong, Jan ;

Skee, Donna ;

Murphy, Joe ;

Sukbuntherng, Juthamas ;

Hellemans, Peter ;

Smit, Johan ;

de Vries, Ronald ;

Jiao, Juhui James ;

Snoeys, Jan ;

Mannaert, Erik .

PHARMACOLOGY RESEARCH & PERSPECTIVES, 2015, 3 (04)

[6] Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling [J].

de Zwart, L. ;

Snoeys, J. ;

De Jong, J. ;

Sukbuntherng, J. ;

Mannaert, E. ;

Monshouwer, M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (05) :548-557

[7] Identification and functional characterization of eight CYP3A4 protein variants [J].

Eiselt, R ;

Domanski, TL ;

Zibat, A ;

Mueller, R ;

Presecan-Siedel, E ;

Hustert, E ;

Zanger, UM ;

Brockmoller, J ;

Klenk, HP ;

Meyer, UA ;

Khan, KK ;

He, YA ;

Halpert, JR ;

Wojnowski, L .

PHARMACOGENETICS, 2001, 11 (05) :447-458

[8] The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy [J].

Honigberg, Lee A. ;

Smith, Ashley M. ;

Sirisawad, Mint ;

Verner, Erik ;

Loury, David ;

Chang, Betty ;

Li, Shyr ;

Pan, Zhengying ;

Thamm, Douglas H. ;

Miller, Richard A. ;

Buggy, Joseph J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (29) :13075-13080

[9]

Hsieh KP, 2001, DRUG METAB DISPOS, V29, P268

[10] Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population [J].

Hu, Guo-Xin ;

Dai, Da-Peng ;

Wang, Hao ;

Huang, Xiang-Xin ;

Zhou, Xiao-Yang ;

Cai, Jie ;

Chen, Hao ;

Cai, Jian-Ping .

PHARMACOGENOMICS, 2017, 18 (04) :369-379

← 1 2 3 →